Abivax seeks partners - Dr. Hartmut Ehrlich, CEO, Abivax 00:00:00
Abivax, a French clinical stage antiviral company, is using some of the EUR 58 million it raised in its June 2015 IPO to finance the late development of a promising anti-HIV compound and a potential therapeutic vaccine against chronic hepatitis B. CEO Dr. Hartmut Ehrlich reveals